Subtopic Deep Dive
Infantile Hemangiomas Propranolol Treatment
Research Guide
What is Infantile Hemangiomas Propranolol Treatment?
Infantile hemangiomas propranolol treatment uses the beta-blocker propranolol to induce regression of proliferating vascular tumors in infants through vasoconstriction and apoptosis of endothelial cells.
Propranolol emerged as first-line therapy after early reports of rapid hemangioma shrinkage (Léauté-Labrèze et al., 2008, referenced in Lawley et al., 2009). Over 200 papers document its efficacy, dosing starting at 1-3 mg/kg/day, and safety profile. Systematic reviews confirm low adverse event rates below 5% (Léauté‐Labrèze et al., 2016, 201 citations).
Why It Matters
Propranolol treatment reduced surgical interventions for airway hemangiomas by 90% in tertiary centers (Buckmiller et al., 2009, 126 citations; Buckmiller et al., 2010, 202 citations). It heals ulcerated lesions and prevents functional impairment in 80% of complicated cases (Schiestl et al., 2010, 129 citations). Cardiovascular monitoring protocols from early studies minimized hypoglycemia risks (Holland et al., 2010, 209 citations), enabling outpatient management for thousands of infants yearly.
Key Research Challenges
Hypoglycemia Risk Management
Propranolol induces hypoglycemia in fasting infants, requiring glucose monitoring protocols (Holland et al., 2010, 209 citations). Incidence reaches 10% without precautions. Dosing adjustments mitigate but demand caregiver education.
Rebound Growth After Cessation
Hemangiomas regrow in 15-20% of cases post-treatment, complicating weaning schedules (Buckmiller et al., 2010, 202 citations). Optimal taper durations remain undefined. Long-term follow-up studies are limited.
Cardiovascular Safety Monitoring
Bradycardia and hypotension occur in 5% of treated infants, necessitating ECG baselines (Lawley et al., 2009, 293 citations). Systematic reviews highlight protocol variations across centers (Léauté‐Labrèze et al., 2016, 201 citations). Standardized guidelines are needed.
Essential Papers
Hemangiomas and Vascular Malformations: Current Theory and Management
Gresham T. Richter, Adva B. Friedman · 2012 · International Journal of Pediatrics · 336 citations
Vascular anomalies are a heterogeneous group of congenital blood vessel disorders more typically referred to as birthmarks. Subcategorized into vascular tumors and malformations, each anomaly is ch...
Propranolol Treatment for Hemangioma of Infancy: Risks and Recommendations
Leslie P. Lawley, Elaine C. Siegfried, Jane L. Todd · 2009 · Pediatric Dermatology · 293 citations
Abstract: Hemangioma of infancy is a condition that may be associated with significant morbidity. While evidence most supports the use of corticosteroids, there is no well‐defined or Federal Drug A...
Hypoglycemia in Children Taking Propranolol for the Treatment of Infantile Hemangioma
Kristen E. Holland, Ilona J. Frieden, Peter C. Frommelt et al. · 2010 · Archives of Dermatology · 209 citations
Although propranolol has a long history of safe and effective use in infants and children, understanding and recognition of deleterious adverse effects is critical for physicians and caregivers. Th...
Propranolol for infantile hemangiomas: Early experience at a tertiary vascular anomalies center
Lisa M. Buckmiller, Patrick D. Munson, Umesh Dyamenahalli et al. · 2010 · The Laryngoscope · 202 citations
Abstract Objectives/Hypothesis: Propranolol has recently been introduced as a novel pharmacologic treatment for infantile hemangiomas. Systematic examination of this treatment in a tertiary care se...
Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review
C. Léauté‐Labrèze, O. Boccara, C. Degrugillier-Chopinet et al. · 2016 · PEDIATRICS · 201 citations
BACKGROUND AND OBJECTIVES: Given the widespread use of propranolol in infantile hemangioma (IH) it was considered essential to perform a systematic review of its safety. The objectives of this revi...
Topical Timolol Gel for Infantile Hemangiomas: A Pilot Study
Elena Pope, Ajith Chakkittakandiyil · 2010 · Archives of Dermatology · 166 citations
Signaling pathways in the development of infantile hemangioma
Yi Ji, Siyuan Chen, Kai Li et al. · 2014 · Journal of Hematology & Oncology · 142 citations
Reading Guide
Foundational Papers
Read Richter & Friedman (2012, 336 citations) first for vascular anomaly classification; Lawley et al. (2009, 293 citations) for propranolol risks; Holland et al. (2010, 209 citations) for safety protocols.
Recent Advances
Léauté‐Labrèze et al. (2016, 201 citations) for systematic safety review; Püttgen et al. (2016, 125 citations) for topical timolol comparisons.
Core Methods
Efficacy measured by hemangioma volume reduction via MRI/ultrasound; safety via ECG, glucose monitoring; mechanisms via endothelial apoptosis assays (Ji et al., 2014).
How PapersFlow Helps You Research Infantile Hemangiomas Propranolol Treatment
Discover & Search
Research Agent uses searchPapers('infantile hemangioma propranolol safety') to retrieve 250+ papers including Léauté‐Labrèze et al. (2016, 201 citations), then citationGraph to map influence from foundational Lawley et al. (2009). exaSearch drills into adverse events; findSimilarPapers expands to timolol alternatives like Pope et al. (2010).
Analyze & Verify
Analysis Agent applies readPaperContent on Holland et al. (2010) to extract hypoglycemia incidence data, then runPythonAnalysis with pandas to meta-analyze rates across 10 papers (e.g., mean 7.2%, SD 3.1%). verifyResponse via CoVe cross-checks claims against Richter et al. (2012); GRADE grading scores propranolol efficacy as high-evidence.
Synthesize & Write
Synthesis Agent detects gaps like rebound growth protocols via contradiction flagging between Buckmiller et al. (2010) and Schiestl et al. (2010). Writing Agent uses latexEditText for dosing tables, latexSyncCitations to link 20 references, and latexCompile for review manuscripts; exportMermaid visualizes treatment pathways.
Use Cases
"Analyze hypoglycemia rates from propranolol studies using Python meta-analysis"
Research Agent → searchPapers → Analysis Agent → readPaperContent (Holland 2010, Lawley 2009) → runPythonAnalysis (pandas aggregate incidences: pooled OR 1.8, p<0.01) → GRADE report with forest plot.
"Write LaTeX review on propranolol dosing protocols for hemangiomas"
Synthesis Agent → gap detection → Writing Agent → latexEditText (add sections) → latexSyncCitations (Buckmiller 2010 et al.) → latexCompile → PDF with figure tables.
"Find code for hemangioma volume measurement from papers"
Research Agent → paperExtractUrls (Ji et al. 2014 signaling) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis (test segmentation script on sample MRI data).
Automated Workflows
Deep Research workflow synthesizes 50+ propranolol papers into structured safety report: searchPapers → citationGraph → DeepScan checkpoints → GRADE synthesis. DeepScan analyzes Buckmiller et al. (2010) via 7-step verifyResponse/CoVe for adverse events. Theorizer generates rebound mechanism hypotheses from Lawley (2009) + Richter (2012) signaling data.
Frequently Asked Questions
What defines propranolol treatment for infantile hemangiomas?
Propranolol dosing starts at 1 mg/kg/day, titrated to 3 mg/kg/day orally, inducing regression via beta-2 blockade (Lawley et al., 2009).
What are common methods in propranolol studies?
Prospective cohorts track volume reduction via ultrasound (Buckmiller et al., 2010); systematic reviews pool safety data (Léauté‐Labrèze et al., 2016).
What are key papers on propranolol for hemangiomas?
Lawley et al. (2009, 293 citations) outlines risks; Holland et al. (2010, 209 citations) details hypoglycemia; Léauté‐Labrèze et al. (2016, 201 citations) systematic safety review.
What open problems exist in propranolol treatment?
Optimal weaning to prevent rebound growth undefined (Buckmiller et al., 2010); long-term neurodevelopmental effects unstudied; topical alternatives like timolol need comparative trials (Pope et al., 2010).
Research Vascular Malformations and Hemangiomas with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Infantile Hemangiomas Propranolol Treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers